Edoxaban or Vitamin K Antagonist for Atrial Fibrillation after TAVR. Reply

Nicolas M. Van Mieghem, Martin Unverdorben, George D. Dangas

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	804
Number of pages	1
Journal	New England Journal of Medicine
Volume	386
Issue number	8
DOIs	https://doi.org/10.1056/NEJMc2120127
State	Published - 24 Feb 2022

Access to Document

@article{191c9a8671824c15a59ad983db543fb0,

title = "Edoxaban or Vitamin K Antagonist for Atrial Fibrillation after TAVR. Reply",

author = "{Van Mieghem}, {Nicolas M.} and Martin Unverdorben and Dangas, {George D.}",

year = "2022",

month = feb,

day = "24",

doi = "10.1056/NEJMc2120127",

language = "English",

volume = "386",

pages = "804",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachussetts Medical Society",

number = "8",

}

TY - JOUR

T1 - Edoxaban or Vitamin K Antagonist for Atrial Fibrillation after TAVR. Reply

AU - Van Mieghem, Nicolas M.

AU - Unverdorben, Martin

AU - Dangas, George D.

PY - 2022/2/24

Y1 - 2022/2/24

UR - http://www.scopus.com/inward/record.url?scp=85125213369&partnerID=8YFLogxK

U2 - 10.1056/NEJMc2120127

DO - 10.1056/NEJMc2120127

M3 - Letter

C2 - 35196442

AN - SCOPUS:85125213369

SN - 0028-4793

VL - 386

SP - 804

JO - New England Journal of Medicine

JF - New England Journal of Medicine

IS - 8

ER -